HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health reform office prescribed for HHS

This article was originally published in The Tan Sheet

Executive Summary

President Obama orders the creation of the Office of Health Reform within the Department of Health and Human Services to coordinate with its counterpart office in the White House in developing and carrying out the president's health reform goals. The April 8 executive order adds that the health reform office will engage in public outreach, work with Congress and agencies to eliminate health care barriers and gather input on policy measures to meet the president's health care goals. Obama's health reform advisor, Nancy-Ann DeParle, leads the White House office, and congressional staffers say health policy expert Jeanne Lambrew will head the HHS office. Lambrew was slated to serve as Tom Daschle's deputy in the White House health reform office and has served at HHS since Daschle's withdrawal as HHS secretary-designate (1"The Tan Sheet" Feb. 23, 2009, p. 12)

You may also be interested in...



Lambrew’s Departure Would Leave Clean Slate For Incoming Health Czar

The expected departure of White House Office of Health Care Reform Deputy Director Jeanne Lambrew allows the next Health and Human Services secretary complete flexibility to bring in key health policy personnel as the Obama administration readies for an intense health reform debate in the coming months

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS135567

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel